Inventor
YEN YUN
US24 patents
⚠️ This page may combine multiple inventors who share the name “YEN YUN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
YEN YUN
5 patentsUS7157570B2Jan 2, 2007
Human ribonucleotide reductase M2 subunit
YEN YUN161 citations97
US8163783B2Apr 24, 2012
Ribonucleotide reductase inhibitors and methods of use
YEN YUN6 citations79
US9029089B2May 12, 2015
Methods for predicting survival in cancer patients
YEN YUN0 citations40
US8859239B2Oct 14, 2014
Methods for small RNA sequencing
YEN YUN0 citations37
US10072294B2Sep 11, 2018
Ultra-high sensitive monitoring of early transplantation failure
YEN YUN0 citations35
CALGENT BIOTECHNOLOGY CO LTD
5 patentsUS11919858B2Mar 5, 2024
Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
CALGENT BIOTECHNOLOGY CO LTD0 citations60
US11084786B2Aug 10, 2021
Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
CALGENT BIOTECHNOLOGY CO LTD0 citations60
US12453708B2Oct 28, 2025
Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
CALGENT BIOTECHNOLOGY CO LTD0 citations57
US11833122B2Dec 5, 2023
Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
CALGENT BIOTECHNOLOGY CO LTD0 citations57
US10745350B2Aug 18, 2020
Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
CALGENT BIOTECHNOLOGY CO LTD0 citations49
UNIV TAIPEI MEDICAL
4 patentsUS10577328B2Mar 3, 2020
Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
UNIV TAIPEI MEDICAL0 citations51
US10246455B2Apr 2, 2019
Histone deacetylase inhibitors
UNIV TAIPEI MEDICAL0 citations49
US10624897B2Apr 21, 2020
Chlorobenzene substituted azaaryl compounds
UNIV TAIPEI MEDICAL0 citations41
US10745433B2Aug 18, 2020
Compounds for inhibiting cancer and virus
UNIV TAIPEI MEDICAL0 citations34
HOPE CITY
3 patentsUS7956076B2Jun 7, 2011
Ribonucleotide reductase inhibitors and methods of use
HOPE CITY9 citations80
US10201530B2Feb 12, 2019
Treatment of BRCA1-defective cancer or resistant cancers
HOPE CITY0 citations51
US9931322B2Apr 3, 2018
Treatment of BRCA1-defective cancer or resistant cancers
HOPE CITY1 citations51